Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD
Authors:
- Denis E. O'DonnellDODenis E. O'Donnell
- Frank SciurbaFSFrank Sciurba
- Bartolome CelliBCBartolome Celli
- Donald A. MahlerDMDonald A. Mahler
- Katherine A. WebbKWKatherine A. Webb
- Chris J. KalbergCKChris J. Kalberg
- Katharine KnobilKKKatharine Knobil
- 1 September 2006
- Vol. 130 (3) , 647-656
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Improvements in Symptom-Limited Exercise Performance Over 8 h With Once-Daily Tiotropium in Patients With COPDChest, 2005
- Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEuropean Respiratory Journal, 2004
- Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPDThorax, 2004
- Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialThe Lancet, 2003
- ATS/ACCP Statement on Cardiopulmonary Exercise TestingAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Dynamic Hyperinflation and Exercise Intolerance in Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2001
- The Effects of Oxitropium Bromide on Exercise Performance in Patients with Stable Chronic Obstructive Pulmonary Disease: A Comparison of Three Different Exercise TestsAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Measurement of Symptoms, Lung Hyperinflation, and Endurance during Exercise in Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 1998
- The Measurement of DyspneaChest, 1984
- Bronchial component in chronic obstructive lung diseaseThe American Journal of Medicine, 1974